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Vaso-occlusive disorders such as in-stent reste-
nosis, vein-graft stenosis, and transplant vasculop-
athy involve formation of intimal hyperplasia, 
i.e., accumulation of vascular smooth muscle 
cells (VSMCs) in the intimal vessel wall layer 
(Motwani  and  Topol,  1998;  Schwartz  and 
Henry, 2002; Mitchell and Libby, 2007). In-
timal hyperplasia can significantly narrow the 
vessel lumen, and it also provides a substrate 
for lipoprotein retention leading to acceler-
ated atherosclerosis (Schwartz et al., 1995; 
Williams and Tabas, 1995; Nakashima et al., 
2008). Activation of quiescent VSMCs to re-
spond to migratory and proliferative stimuli is 
an important step in the formation of intimal 
hyperplasia (Clowes et al., 1983; Newby and 
Zaltsman, 2000). Hence, selectively blocking 
expansion of activated VSMCs is a potential 
strategy to reduce intimal hyperplasia with-
out affecting normal vasculature with resident 
quiescent VSMCs.
CD98 (4F2 antigen, FRP-1) is a transmem-
brane heterodimer composed of one CD98 heavy 
chain (CD98hc), the product of the Slc3a2 gene 
(also known as 4F2hc), and one out of six differ-
ent CD98-associated light chains (Wagner et al., 
2001). CD98 is involved in cell proliferation and 
survival (Yagita and Hashimoto, 1986; Diaz et al., 
1997; Liu et al., 2004; Féral et al., 2005) and 
is  highly  expressed  in  proliferating  tissues 
(Hashimoto et al., 1983; Masuko et al., 1985). 
CD98 has two distinct functions, integrin sig-
naling and amino acid transport, and these func-
tions are dependent on different domains of 
CD98hc. The intracellular and transmembrane 
domains of CD98hc interact with 1 and 3 in-
tegrins and promote integrin outside-in signaling, 
(Zent et al., 2000; Fenczik et al., 2001; Féral et al., 
2005; Prager et al., 2007), whereas the extracel-
lular domain of CD98hc binds to CD98 light 
chains, targeting them to the plasma membrane 
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Activation of vascular smooth muscle cells (VSMCs) to migrate and proliferate is essential 
for the formation of intimal hyperplasia. Hence, selectively targeting activated VSMCs is a 
potential strategy against vaso-occlusive disorders such as in-stent restenosis, vein-graft 
stenosis, and transplant vasculopathy. We show that CD98 heavy chain (CD98hc) is mark-
edly up-regulated in neointimal and cultured VSMCs, and that activated but not quiescent 
VSMCs require CD98hc for survival. CD98hc mediates integrin signaling and localizes amino 
acid transporters to the plasma membrane. SMC-specific deletion of CD98hc did not affect 
normal vessel morphology, indicating that CD98hc was not required for the maintenance of 
resident quiescent VSMCs; however, CD98hc deletion reduced intimal hyperplasia after 
arterial injury. Ex vivo and in vitro, loss of CD98hc suppressed proliferation and induced 
apoptosis in VSMCs. Furthermore, reconstitution with CD98hc mutants showed that 
CD98hc interaction with integrins was necessary for the survival of VSMCs. These studies 
establish the importance of CD98hc in VSMC proliferation and survival. Furthermore, loss 
of CD98hc was selectively deleterious to activated VSMCs while sparing resident quiescent 
VSMCs, suggesting that activated VSMCs are physiologically dependent on CD98hc, and 
hence, CD98hc is a potential therapeutic target in vaso-occlusive disorders.
© 2009 Fogelstrand et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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fibronectin/gelatin matrix in the presence of 0.2% fetal calf 
serum. These cultured VSMCs uniformly expressed CD98 at 
high levels (GMF = 325). Because the formation of intimal 
hyperplasia involves a change of extracellular matrix (e.g., a 
change from laminin to fibronectin) and secretion of growth 
factors, we examined how these factors regulated CD98 ex-
pression in cultured VSMCs. The VSMCs were first made 
quiescent on Matrigel for 2 d and then replated on laminin-1 
or fibronectin with or without platelet-derived growth factor 
(PDGF)–BB for 24 h. Fibronectin significantly increased the 
CD98 expression compared with laminin-1, and PDGF-BB 
up-regulated the CD98 expression on both matrices (Fig. 1 E). 
In summary, quiescent VSMCs in uninjured vessels expressed 
CD98 at low levels, whereas vascular injury and tissue culture 
conditions dramatically increased VSMC CD98 expression. 
Furthermore, the VSMC CD98 expression was regulated by 
both extracellular matrix and growth factors.
Grossly normal vasculature in the absence of VSMC CD98hc
To assess the importance of CD98 for VSMC function in 
vivo, we specifically deleted CD98hc in SMCs by crossing 
mice bearing a conditional null Slc3a2 allele (Slc3a2fl/fl; Fig. 2 A; 
Féral et al., 2007) with SM22-Cre transgenic mice that ex-
press Cre recombinase under an SMC-specific promoter 
(Lepore et al., 2005). In the Slc3a2fl/flSM22-Cre mice, the 
Slc3a2fl/fl gene was deleted in >97% of aortic SMCs and CD98 
protein was undetectable (Fig. 2, B and C). Despite almost 
complete loss of VSMC CD98, vascular morphology was ap-
parently normal as judged by histological examination of the 
CA, the aorta, the femoral artery, the internal jugular vein, 
and the inferior vena cava (Fig. S2). The functional integrity 
of the vasculature was confirmed by the normal morphology 
of highly vascularized tissues such as lung and liver (Fig. S2), 
and the normal viability, fertility, and weight gain of Slc3a2fl/fl 
SM22-Cre male and female mice (not depicted). We also 
examined the dorsal aorta at embryonic day 13.5 in Slc3a2fl/fl 
SM22-Cre embryos (n = 7) and Slc3a2fl/fl controls (n = 2). 
In control embryos, the vascular cells expressed CD98 at high 
levels. In the Slc3a2fl/flSM22a-Cre embryos, the CD98 ex-
pression was significantly lower, but most vascular cells still 
stained positive for CD98 (Fig. S3). However, there was no 
obvious morphological difference between the two groups. 
Collectively, VSMC CD98hc is not necessary for normal 
vessel morphology under conditions where VSMCs manifest 
the quiescent phenotype.
VSMC CD98hc is required for neointima formation  
in injured CAs
Because cultured and neointimal VSMCs expressed CD98 
at high levels, we assessed whether CD98hc is necessary for 
neointima formation after arterial injury. Slc3a2fl/flSM22-
Cre mice (n = 8) and littermate controls (Slc3a2fl/fl; n = 10) 
were subjected to the carotid injury described in Fig. 1 B.   
3 wk after surgery, there was a dramatic decrease (>70%) in 
neointimal area in the Slc3a2fl/flSM22-Cre mice compared 
with littermate controls (Fig. 3, A and B). Furthermore, in 
where they mediate amino acid transport (Fenczik et al., 2001; 
Wagner et al., 2001).
Because CD98 is involved in cell proliferation and sur-
vival, we hypothesized a role for VSMC CD98 in the forma-
tion of intimal hyperplasia after vascular injury. In this paper, 
we show that CD98 is markedly up-regulated in VSMCs 
activated by vascular injury or by growth factors, and that 
VSMCs with high CD98 expression are dependent on CD98hc 
for survival. Using a CD98hc conditional null mouse, we 
show that VSMC CD98hc is not needed for normal vascular 
morphology but is required for neointimal formation after 
arterial injury. Deletion of VSMC CD98hc both suppresses 
proliferation and induces apoptosis of VSMCs, thus provid-
ing a mechanism for its effect on intimal hyperplasia. Fur-
thermore, using reconstitution with CD98hc mutants, we 
show that the region of CD98hc that interacts with integrins 
is essential for VSMC survival, whereas the region that medi-
ates amino acid transport is dispensable. These findings show 
that loss of CD98hc is selectively deleterious to activated 
VSMCs with high CD98 expression while sparing resident 
quiescent VSMCs, suggesting CD98hc as a potential thera-
peutic target in vaso-occlusive disorders.
RESULTS
Expression of CD98 in VSMCs
To assess a potential role of CD98 in VSMC biology, we first 
analyzed CD98 expression in uninjured and injured arteries 
of wild-type mice. In uninjured carotid arteries (CAs) and 
aortas (n = 3), faint CD98 staining was seen among the qui-
escent VSMCs in the media (Fig. 1 A and not depicted). To 
examine  VSMC  CD98  expression  in  injured  vessels,  we 
modified  a  mouse  model  of  carotid  intimal  hyperplasia 
(Fig. 1 B, illustrations; Simon et al., 2000). Medial injury was 
induced by pressure dilation, the endothelium was removed 
with a nylon fishing line, and flow was reduced by ligation of 
the external and internal CAs, thus leaving only the occipital 
artery open at the carotid bifurcation. In this model, a cir-
cumferential neointima was formed 3 wk after injury (Fig. 1 B, 
photomicrographs). Importantly, this model allowed a neo-
intima to be formed in the presence of the remaining medial 
VSMCs as well as in the presence of a blood flow, making 
it suitable for SMC-specific gene knockout. In the injured 
CA (n = 3), there was a dramatic increase in CD98 expression 
in the neointima and among scattered cells in the underlying 
media (Fig. 1 C). We used flow cytometry to quantify CD98 
expression in VSMCs and excluded a contribution from en-
dothelial cells or leukocytes by eliminating CD31- and CD18- 
positive cells (Fig. S1). In uninjured vessels, we detected a 
single population of VSMCs that expressed modest levels of 
CD98. In sharp contrast, there was an additional CD98 bright 
population in the injured vessels (Fig. 1 D). Quantification of 
these data revealed an approximately sixfold increase in CD98 
expression in the CD98 bright population (uninjured geo-
metric mean fluorescence (GMF) = 40, injured CD98 dull 
GMF = 38, and CD98 bright GMF = 249). We also exam-
ined CD98 expression in cultured VSMCs plated on a mixed JEM VOL. 206, October 26, 2009 
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caused by selection of cells in which the Slc3a2fl/fl gene is 
retained intact.
CD98hc is important for VSMC explant outgrowth, 
proliferation, and survival
To study VSMCs ex vivo, we isolated the medial vessel wall 
layer of thoracic aortas and incubated these VSMC explants in 
DMEM with 10% serum (n = 6 aortas in each group). In a 
preliminary experiment, the number of VSMCs that grew out 
Slc3a2fl/flSM22-Cre mice, the injured vessels (intima + 
media) contained some CD98-positive VSMCs (Fig. 3 C). 
In these flow cytometry studies, endothelial cells (CD31 
positive) and leukocytes (CD18 positive) were excluded in 
the analyses. The presence of these CD98 bright cells sug-
gests that there was a strong selection for CD98-positive 
cells during the neointima formation. Collectively, VSMC 
CD98hc is required for intimal hyperplasia, and the neo-
intima that forms in the Slc3a2fl/flSM22-Cre mice is likely 
Figure 1.  CD98 expression in VSMCs. (A) Uninjured mouse CA stained for CD98 (green; left) or isotype control (right). The lumen is facing up, and 
double arrows indicate the vessel media. Note the faint green CD98 staining of VSMCs in between the autofluorescent elastic laminae. Data in this panel 
and in C are representative of one out of three mice so studied. Bar, 25 µm. (B) Mouse CA injury model. (illustrations) Saline dilates the common CA  
(91 Pa for 20 s), followed by endothelial denudation with a nylon wire and restoration of a reduced blood flow. (photomicrographs) Injured (day 21) and 
uninjured CA. Arrows indicate the internal elastic lamina. Brown staining indicates SM22 immunostaining. Bar, 100 µm. (C) Expression of CD98 14 d 
after carotid injury. Note the bright CD98 staining in the neointima. (D) Cellular expression of VSMC CD98 in CAs (intima + media) analyzed by flow cytom-
etry. Endothelial cells (CD31 positive) and leukocytes (CD18 positive) were excluded during the data analyses. Note the CD98 bright VSMC population 
after vascular injury (arrow). The experiment was performed twice. Three injured CAs and three uninjured CAs were pooled in each experiment. (E) Extra-
cellular matrix and PDGF-BB regulate CD98 expression in cultured mouse VSMCs. VSMCs were differentiated on Matrigel and replated on either laminin-
1 (Lm) or fibronectin (Fn) with or without 20 ng/ml PDGF-BB. After 24 h, the replated cells were analyzed for CD98 by flow cytometry. Data are presented 
as means ± SEM (n = 6 in each group). Data are from two independent experiments.2400 DEPENDENCE OF ACTIVATED VSMCS ON CD98HC | Fogelstrand et al.
explants also exhibited a 1.8-fold increase in apoptosis relative 
to control explants (Fig. 4 C, right). Thus, CD98hc is impor-
tant for VSMC proliferation and survival.
CD98hc is required for VSMC survival in vitro
To precisely define the mechanism by which CD98hc medi-
ates VSMC expansion, we acutely deleted the CD98hc gene 
in cultured VSMCs. Slc3a2fl/fl VSMCs were isolated from the 
thoracic aorta and the CD98hc gene was deleted using adeno-
virus encoding Cre recombinase (Adeno-Cre); control Slc3a2fl/fl 
VSMCs were infected with adenovirus encoding -galactosidase 
(Adeno-LacZ). The efficiency of CD98hc gene deletion 
was judged by flow cytometry for CD98. At day 4 after 
from Slc3a2fl/flSM22-Cre explants after 4 d was markedly re-
duced (>70%) compared with Slc3a2fl/fl controls (Fig. 4 A). 
Within the Slc3a2fl/flSM22-Cre explant tissues, all VSMCs 
were negative for CD98 protein (Fig. 4 B, left). However, a 
selection for CD98-positive cells was observed in the out-
grown cells; specifically, 78% of VSMCs that grew out from 
Slc3a2fl/flSM22-Cre explants were CD98 positive (Fig. 4 B, 
right). The strong selection against CD98-null VSMCs in in-
jured vessels in vivo and in explant outgrowths ex vivo could 
have been caused by increased cell death or a lack of prolifera-
tion. To examine these possibilities, explant tissues at day 4 
were processed for histological analyses of proliferation (BrdU 
incorporation over 2 h; n = 6 in each group) and apoptosis 
(Tdt-mediated dUTP-biotin nick-end labeling [TUNEL] 
assay; n = 6 in each group). In Slc3a2fl/flSM22-Cre explants, 
there were very few proliferating cells (0.3 ± 0.1%), in con-
trast to Slc3a2fl/fl control explants that exhibited 2.9 ± 0.4% 
proliferating cells (Fig. 4 C, left). The Slc3a2fl/flSM22-Cre 
Figure 2.  Deletion of CD98hc in Slc3a2fl/flSM22-Cre mice.  
(A) Exons 1 and 2 in the Slc3a2fl/fl gene are flanked by loxP sites (closed 
triangles; top). After exposure to Cre recombinase, these exons, includ-
ing the start codon (arrow on exon 1), will be excised (bottom) and 
CD98hc will not be expressed. (B) Efficiency of Slc3a2fl/fl gene deletion. 
The media from the thoracic aorta was isolated from Slc3a2fl/flSM22-
Cre mice (n = 3) and Slc3a2fl/fl littermate controls (n = 3). The relative 
presence of the Slc3a2fl/fl gene (normalized to the 4 integrin gene) was 
quantified with real-time PCR. Data are presented as means ± SEM and 
are from one experiment. (C) Loss of VSMC CD98 protein expression. 
Single-cell suspensions were prepared from the media of thoracic aortas 
and analyzed by flow cytometry for CD98 (continuous lines; the dotted 
lines indicate isotype control). (top) VSMCs from Slc3a2fl/flSM22-Cre 
mice. (bottom) VSMCs from Slc3a2fl/fl mice. Two aortas were pooled in 
each group. The experiment was performed twice.
Figure 3.  VSMC CD98hc deletion inhibits neointimal hyperplasia. 
(A) Representative images of neointima formation 3 wk after carotid in-
jury in Slc3a2fl/flSM22-Cre mice (top) and Slc3a2fl/fl littermate controls 
(bottom). Arrows indicate the internal elastic lamina, which demarcates 
the intima from the media. Bar, 100 µm. (B) Quantification of neointimal 
area (pixels) in Slc3a2fl/flSM22-Cre mice (n = 8) and Slc3a2fl/fl littermates 
(n = 10). Data are presented as means ± SEM. P = 0.0006. (C) Cellular ex-
pression of VSMC CD98 in Slc3a2fl/flSM22-Cre mice (n = 3) and Slc3a2fl/fl 
mice (n = 3) 14 d after carotid injury. The adventitias were removed, and 
the remaining tissues (intima + media) in each group were pooled and 
processed for flow cytometry for CD98. Endothelial cells (CD31 positive) 
and leukocytes (CD18 positive) were excluded in the data analyses. The 
dotted line indicates IgG2a isotype control. Note the bright CD98-positive 
population in the injured CAs from Slc3a2fl/flSM22-Cre mice (arrow). The 
figure is representative of two independent experiments.JEM VOL. 206, October 26, 2009 
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show that CD98hc is markedly up-regulated in VSMCs 
stimulated by vascular injury and by in vitro cell-culturing 
conditions. Furthermore, using SMC-specific deletion of 
Figure 4.  CD98hc is required for VSMC outgrowth, proliferation, 
and survival ex vivo. (A) Outgrown cells from media explants cultured in 
10% serum were enumerated at day 4. (top) Slc3a2fl/flSM22-Cre explant. 
(bottom) Slc3a2fl/fl littermate explant. The bar graph quantifies outgrown 
cells from Slc3a2fl/flSM22-Cre explants and Slc3a2fl/fl controls (n = 6 ex-
plants from six mice in each group for a total of 72 explants). Data are pre-
sented as means ± SEM and are from one experiment. Bar, 100 µm. (B) CD98 
expression in digested explant tissues (left) and in outgrown cells (right) 
analyzed by flow cytometry. The dotted line indicates IgG2a antibody con-
trol. Explants from six mice were pooled in each group. The experiment was 
performed twice with identical results. (C) Proliferation and apoptosis within 
explant tissues at day 4. (left) Proliferation index (percentage of BrdU-posi-
tive cells). (right) Apoptosis index (percentage of TUNEL-positive cells). Data 
are presented as means ± SEM (n = 6 explants from six mice in each group).
Adeno-Cre infection, >95% of the cells had reduced CD98 
protein expression to <10% of that seen in Adeno-LacZ– 
infected cells (unpublished data). To assess the importance of 
CD98hc for VSMC survival, we enumerated the number of 
live cells (propidium iodide [PI]–negative cells) at various times 
after adenovirus infection. The cells were cultured in limiting 
serum (0.2% serum). Beginning 5 d after Adeno-Cre infec-
tion, there was a reduction of 85 ± 3.1% in viable VSMCs, 
and by day 6, 98 ± 0.5% of the VSMCs were lost (compared 
with Adeno-Cre–infected VSMCs at day 3). Among Adeno-
LacZ–infected VSMCs, there was <10% loss of live cells at 
days 5 (9.2 ± 2.4%) and 6 (8.1 ± 7.5%) compared with day 3 
(Fig. 5 A). The massive cell death was most likely caused by 
apoptosis, because the Adeno-Cre–treated cells stained posi-
tive for TUNEL assay (Fig. 5 B) and exhibited activated 
caspase-1/3, as assessed by staining with FITC-zVAD-FMK 
(CaspACE; Fig. 5 C). Because PDGF-BB up-regulated CD98 
expression in cultured VSMCs (Fig. 1 E), we also examined the 
effect of this growth factor on VSMC survival after CD98hc 
gene deletion. Stimulation with PDGF-BB or 10% serum 
caused Adeno-Cre–treated VSMCs to undergo accelerated 
cell death compared with cells in low serum conditions 
(Fig. 5 D). In conclusion, CD98hc is necessary for the survival 
of cultured VSMCs; i.e., they are physiologically dependent 
on their CD98hc expression and the CD98hc dependence is 
exacerbated by growth factor stimulation.
The region of CD98hc that interacts with integrins but not 
amino acid transporters supports VSMC survival
CD98hc can mediate both integrin signaling and amino acid 
transport. The integrin function is dependent on both the 
cytoplasmic and transmembrane domain, whereas the extra-
cellular domain is necessary for amino acid transport. To as-
sess which domains of CD98hc were important for VSMC 
survival, CD98hc-deficient VSMCs (Adeno-Cre treated) were 
reconstituted with full-length CD98hc, full-length CD69, 
and three CD98hc-CD69 chimeras in which the cytoplasmic 
(C69T98E98), the transmembrane (C98T69E98), or the ex-
tracellular (C98T98E69) domain had been switched to CD69 
(Fig. 6 A; Fenczik et al., 2001; Féral et al., 2005). CD69 is a 
type II transmembrane protein, but it is not known to bind 
integrins or CD98 light chains. Full-length CD98hc and the 
chimera that supports integrin function (C98T98E69) rescued 
CD98hc-deficient VSMCs from apoptosis. In sharp contrast, 
full-length CD69 and the chimeras that support amino acid 
transport function (C69T98E98 and C98T69E98) did not 
rescue VSMCs from apoptosis (Fig. 6 B). Hence, the do-
mains of CD98hc that associate with integrins are essential 
for VSMC survival.
DISCUSSION
Vaso-occlusive disorders, such as in-stent restenosis, vein-graft 
stenosis, and transplant vasculopathy, involve intimal hyper-
plasia, which is caused by an activation of VSMCs to migrate 
and proliferate (Motwani and Topol, 1998; Schwartz and 
Henry, 2002; Mitchell and Libby, 2007). In this paper, we 2402 DEPENDENCE OF ACTIVATED VSMCS ON CD98HC | Fogelstrand et al.
cultured VSMCs, and the CD98hc expression was up-regu-
lated by fibronectin and PDGF-BB. Thus, in three different 
experimental systems (in vivo, ex vivo, and in vitro) CD98hc 
was up-regulated in activated VSMCs and can therefore   
be considered an activation marker. The first intron of the 
CD98hc gene contains a transcriptional enhancer element that 
is tightly regulated coordinately with cell proliferation, sug-
gesting that this element is responsible for the increased CD98hc 
in activated VSMCs (Karpinski et al., 1989).
Strikingly, deletion of CD98hc in VSMCs did not seem 
to affect quiescent VSMCs in the normal vasculature. In the 
Slc3a2fl/flSM22-Cre embryo, a slow turnover of the CD98 
protein after gene deletion might have enabled the vasculature 
to develop. Indeed, we found residual CD98 expression at 
embryonic day 13.5 (Fig. S3), which is 4 d after the SM22-Cre 
transgene is reported to be expressed (Lepore et al., 2005). 
The finding that a mature vasculature can form and function 
without VSMC CD98hc shows that CD98hc can be inhib-
ited without lethal effects on resting quiescent VSMCs. In 
contrast to quiescent VSMCs, CD98hc was required for acti-
vated VSMCs during the formation of intimal hyperplasia 
and for cultured VSMCs. The selective effect of CD98hc de-
letion on activated VSMCs suggests that VSMC activation leads 
to a dependence on CD98hc for their survival. This dependence 
CD98hc, we show that loss of VSMC CD98hc is compatible 
with normal vessel morphology; however, CD98hc is required 
for formation of a neointima after arterial injury. The mecha-
nism of this effect of VSMC CD98hc deletion was both sup-
pression of proliferation and induction of apoptosis. CD98hc 
has two distinct functions, amino acid transport and interac-
tion with integrins to enhance integrin signaling. Using re-
constitution with CD98hc mutants, we show that the moiety 
of CD98hc that interacts with integrins and mediates integrin 
signaling is necessary and sufficient for the survival of VSMCs. 
These studies are the first to establish the role of CD98hc in 
VSMC proliferation and survival, and show that the ability of 
CD98hc to interact with integrins is essential for these func-
tions. Furthermore, loss of CD98hc is selectively deleterious 
to activated VSMCs with high CD98 expression while spar-
ing resident quiescent VSMCs, explaining its capacity to block 
neoinitima formation and indicating that CD98hc is a poten-
tial therapeutic target in vaso-occlusive disorders.
The present study shows that CD98hc expression is up-
regulated when VSMCs are stimulated by vascular injury and 
growth factors. CD98hc expression was low in quiescent 
resting VSMCs in the aorta and CA but was markedly in-
creased after vessel injury. Furthermore, CD98hc expression 
was high in VSMCs that grew out from tissue explants and in 
Figure 5.  CD98hc is required for survival of cultured VSMCs. (A) The relative number of live Slc3a2fl/fl VSMCs estimated by flow cytometry 3, 4, 5, 
and 6 d after CD98hc gene deletion with Adeno-Cre. Data are presented as means ± SEM (n = 3 in each group). ***, P < 0.001. (B) TUNEL staining of  
Slc3a2fl/fl VSMCs 5 d after Adeno-Cre and Adeno-LacZ treatment. Bar, 100 µm. (C) Caspase-1/3 activity demonstrated by flow cytometry (CaspACE) in 
Slc3a2fl/fl VSMCs 4 d after adenovirus treatment. (D) Growth factor stimulation increases the loss of CD98hc-deficient VSMCs. At day 3.5, adenovirus-
infected Slc3a2fl/fl VSMCs were treated with 20 ng/ml PDGF-BB, 10% serum, or 0.2% serum. At day 4, the relative number of live cells was assessed by 
flow cytometry. Data are presented as means ± SEM (n = 3 for each group). Data in A and D are from three experiments, and the experiments in B and C 
were performed twice with identical results.JEM VOL. 206, October 26, 2009 
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Wagner et al., 2001), and the transmembrane and cytoplasmic 
domains of CD98hc mediate interaction with  integrin sub-
units and the generation of survival signals such as activation 
of Akt (Fenczik et al., 1997, 2001; Féral et al., 2005). Recon-
stitution studies with CD98hc-CD69 chimeras showed that 
the integrin-binding moiety of CD98hc was essential for 
the survival of VSMCs. In contrast, the CD98hc chimeras that 
can interact with CD98 light chains to promote amino acid 
transport failed to rescue survival in vitro. Nevertheless, the 
interaction with CD98 light chains might be important in 
the functions of metabolically active VSMCs with a high 
proliferative  rate  and  extensive  protein  synthesis.  Indeed, 
others have reported that blockade of LAT1 and LAT2 
function, two of the six CD98 light chains, can lead to apop-
tosis of PDGF-BB–stimulated VSMCs (Liu et al., 2004). This 
might explain the accelerated cell death among CD98-defi-
cient VSMCs treated with PDGF-BB or serum in our study. 
On the other hand, PDGF-BB also reduces VSMC adhesion 
is remarkably similar to the “addiction” of tumor cells to 
oncogenes, so-called oncogene addiction (Weinstein, 2002). 
For example, inhibition of Abl kinase with Gleevec leads to 
the death of BCR-Abl–expressing chronic myelogenous leu-
kemia leukocytes but has no effect on the survival of normal 
leukocytes (Dan et al., 1998). The mechanism of oncogene 
addiction is uncertain, but one concept is that the presence of 
a given oncogene enhances proliferation/survival as well as 
apoptosis signals. Consequently, cancer cells may be ad-
dicted to the survival activity of the oncogene to avoid apop-
tosis (Weinstein and Joe, 2006). Our data show that the 
CD98 expression in activated VSMCs enables their survival; 
hence, these cells are similarly dependent on CD98hc to 
avoid apoptosis.
CD98hc performs two cellular functions: amino acid trans-
port and integrin signaling. The extracellular domain of CD98hc 
is responsible for amino acid transport through interaction 
with one of several CD98 light chains (Fenczik et al., 2001; 
Figure 6.  The integrin-binding function of CD98hc mediates VSMC survival. (A) Illustration of human CD98hc-CD69 chimeras and their interac-
tion with integrins (integrin signaling) or amino acid transporters (AA transport). CD69 is a type II transmembrane protein not known to bind to integrins 
or CD98 light chains. Each chimera is defined by its cytoplasmic (C), transmembrane (T), and extracellular (E) domain derived from either CD98hc (98; 
gray) or CD69 (69; white). (B) The integrin-binding CD98 chimera rescues CD98hc-deficient VSMCs from cell death. Slc3a2fl/fl VSMCs were infected with  
retrovirus coding for GFP and any of the five human CD98hc-CD69 constructs described in A. The endogenous mouse CD98hc was deleted with Adeno-
Cre. The relative number of reconstituted live cells (GFP positive and PI negative) was assessed by flow cytometry at days 3 and 6 after Adeno-Cre treat-
ment. Data are presented as means ± SEM from three independent experiments.2404 DEPENDENCE OF ACTIVATED VSMCS ON CD98HC | Fogelstrand et al.
a small molecular inhibitor that could selectively kill acti-
vated VSMCs. The interaction sites for CD98hc on the   
1 and 3 integrin tails have been mapped (Prager et al., 2007), 
and recent studies have established the feasibility of develop-
ing cell-permeable inhibitors of integrin cytoplasmic domain 
interactions (Ambroise et al., 2002; Su et al., 2008). RGT, a 
synthetic peptide corresponding to the 3 integrin cytoplas-
mic C-terminal sequence, selectively inhibits outside-in sig-
naling in human platelets by disrupting the interaction of 
IIb3 integrin with Src kinase (Su et al., 2008). Thus, our 
studies establish the selective importance of CD98hc for the 
survival and proliferation of activated VSMCs, show that the 
connection to integrins is important for this activity, and 
identify CD98hc as a potential therapeutic target in vaso-
occlusive disorders.
MATERIALS AND METHODS
Animals and carotid injury. All surgical procedures were approved by the 
Institutional Animal Care and Use Committee at the University of Califor-
nia, San Diego. CD98hc conditional null mice (Slc3a2fl/fl; Féral et al., 2007) 
were crossed with SM22-Cre transgenic mice (Lepore et al., 2005) to delete 
the CD98hc gene (Slc3a2) in SMCs. For all in vivo and ex vivo experiments, 
Slc3a2fl/flSM22-Cre  mice  and  sex-matched  Slc3a2fl/fl  littermate  controls 
aged 7–9 wk were used. The carotid injury model (Fig. 1 B) was based on a 
previously published study (Simon et al., 2000). The CA was dilated at 91 Pa 
for 20 s, and the endothelium was denuded with a nylon wire (0.19 mm in 
diameter). To facilitate neointima formation, the postangioplastic blood flow 
was reduced by leaving only the occipital artery open at the carotid bifurca-
tion (Korshunov and Berk, 2003). Injured arteries were analyzed 450–550 µm 
proximal to the carotid bifurcation. Neointimal area was quantified (pixels) 
using the National Institutes of Health (NIH) Image J software (available at 
http://rsbweb.nih.gov/ij/) on cross sections visualized by autofluorescence 
(excitation wavelength = 488 nm; 530 nm band-pass filter; Fig. 3 A).
Histology and immunohistochemistry. Tissue samples were processed 
and prepared for standard histological and immunohistochemical procedures 
(Fogelstrand et al., 2005). Formalin-fixed tissues were pressure perfused at 
100 mmHg. Formalin-fixed paraffin sections were used for all histology ex-
cept for CD98 immunostaining, which was performed on frozen sections. 
The following antibodies and kits were used: rabbit anti–human SM22 
(Proteintech Group, Inc.), horseradish peroxidase–conjugated goat anti–rab-
bit antibody (SouthernBiotech), rat anti–mouse CD98 (clone RL388; eBio-
science), rat IgG2a isotype control (eBioscience), Alexa Fluor 488–conjugated 
goat anti–rat (Invitrogen), the In Situ Cell Death Detection Kit (Roche), 
and the BrdU Labeling and Detection Kit I (Roche).
Flow cytometry. Immunolabeled cells were analyzed on a flow cytometer 
(FACSCalibur; BD) with CellQuest software (BD). For all vessels, the adven-
titia was removed after a 5-min treatment with 10 mg/ml collagenase at room 
temperature, and the remaining intima + media were digested to a single-cell 
suspension at 37°C in a 10 mg/ml collagenase and 2.5 mg/ml elastase solution 
(Worthington Biochemical Corp.). Endothelial cells (CD31 positive) and 
leukocytes (CD18 positive) were excluded by gating during the data analyses. 
The following antibodies were used: PE-conjugated anti–mouse CD98 (clone 
RL388; eBioscience), PE-conjugated rat IgG2a control antibody (eBioscience), 
FITC-conjugated anti–mouse CD31 (clone MEC 13.3; BD), and FITC-
conjugated anti–mouse CD18 antibodies (clone M18/2; eBioscience). For 
cell counting, cells were trypsinized and resuspended in a fixed volume of PBS 
with 5 µg/ml PI (Invitrogen). The relative number of live cells (PI negative) was 
determined by collecting resuspended cells for 60 s on the flow cytometer.
Aortic media explants. Approximately 1 × 1 mm media explants were 
prepared from the thoracic aorta (Choi et al., 2004). Endothelial cells were 
to fibronectin (Berrou and Bryckaert, 2001), and hence, the 
PDGF-BB–treated cells might have become more susceptible 
to apoptosis as a result of reduced attachment to the extracel-
lular matrix. Clearly, the possible importance of CD98hc in 
VSMC amino acid transport function awaits additional study. 
Interestingly, the LAT1/2 inhibition did not have any effect 
on VSMC proliferation (Liu et al., 2004), suggesting that the 
integrin function and not the amino acid transport function of 
CD98hc regulates VSMC proliferation. In support of this, 
Féral et al. (2005) have shown in teratocarcinomas that the 
integrin-binding portion of CD98hc promotes cell prolifera-
tion. Collectively, the integrin-binding function of CD98hc 
seems to be an important regulator of both VSMC survival 
and proliferation.
VSMC V3 and 51, two integrins that couple to 
CD98hc, (Zent et al., 2000) are key players in the formation 
of intimal hyperplasia. Inhibition of V3 reduces neointima 
formation in several studies (for review see Kokubo et al., 
2007), and 51 is responsible for neointima fibronectin as-
sembly after vascular injury (Pickering et al., 2000). Binding 
of 51 integrin to fibronectin induces a synthetic VSMC 
phenotype and promotes VSMC proliferation and survival 
(Hedin et al., 1997; Mercurius and Morla, 1998; Freyer et al., 
2001; Taylor et al., 2001). CD98hc interaction with integ-
rins is important for pp125FAK-dependent phosphoinositide 
3-kinase activation with downstream activation of Akt and 
phosphorylation of p130CAS leading to Rac activation (Féral 
et al., 2005), and these pathways have been implicated in the 
survival and proliferation of VSMCs (Bai et al., 1999; Stabile 
et al., 2003; Allard et al., 2008; Bond et al., 2008). Thus, sup-
pressed proliferation and increased apoptosis in CD98hc-
deleted VSMCs might be a result of impaired phosphoinositide 
3-kinase–Akt signaling and Rac activation. Deletion of VSMC 
CD98 in vitro led to degradation of pp125FAK before death 
(unpublished data), precluding study of the effects of CD98 
on signaling events linked to pp125FAK. However, our results 
underscore that only activated VSMCs require CD98hc, and 
the CD98hc domains that support integrin function are cru-
cial for VSMC survival, suggesting that activation of VSMCs 
leads cells to become dependent on enhanced integrin signal-
ing for survival.
Our data suggest that inhibition of VSMC CD98hc func-
tion could be therapeutically useful. In particular, we show 
that activated VSMCs with high CD98 expression require 
CD98hc for survival and proliferation, whereas quiescent 
normal VSMCs with low CD98 expression do not. Most 
vascular interventions enable local postangioplastic treatments 
applied in a perivascular gel or attached to an endoluminal 
stent. Local application of small interfering RNA, antisense 
oligonucleotides, or lentiviral-delivered short hairpin RNA 
against CD98hc is a potential therapeutic strategy (Crooke, 
2004; Banno et al., 2006; Akhtar and Benter, 2007). It may 
also be possible to develop blocking antibodies against CD98hc 
that could be locally administered in connection with vascu-
lar surgery (Hashimoto et al., 1983). Finally, our data suggest 
that the integrin–CD98hc interaction is a potential target for JEM VOL. 206, October 26, 2009 
ARTICLE
2405
This study was supported by grants from the NIH (HL 31950, AR27214, and 
HL 078784). P. Fogelstrand held a postdoctoral fellowship from the Swedish Research 
Council, and C.C. Féral held a postdoctoral fellowship from the Arthritis Foundation.
The authors have no conflicting financial interests.
Submitted: 19 December 2008
Accepted: 21 September 2009
REFERENCES
Akhtar, S., and I.F. Benter. 2007. Nonviral delivery of synthetic siRNAs in 
vivo. J. Clin. Invest. 117:3623–3632. doi:10.1172/JCI33494
Allard, D., N. Figg, M.R. Bennett, and T.D. Littlewood. 2008. Akt regulates 
the survival of vascular smooth muscle cells via inhibition of FoxO3a and 
GSK3. J. Biol. Chem. 283:19739–19747. doi:10.1074/jbc.M710098200
Ambroise, Y., B. Yaspan, M.H. Ginsberg, and D.L. Boger. 2002. Inhibitors 
of cell migration that inhibit intracellular paxillin/alpha4 binding: a well-
documented use of positional scanning libraries. Chem. Biol. 9:1219–1226. 
doi:10.1016/S1074-5521(02)00246-6
Bai, H., M.J. Pollman, Y. Inishi, and G.H. Gibbons. 1999. Regulation of 
vascular smooth muscle cell apoptosis. Modulation of bad by a phospha-
tidylinositol 3-kinase-dependent pathway. Circ. Res. 85:229–237.
Banno, H., Y. Takei, T. Muramatsu, K. Komori, and K. Kadomatsu. 2006. 
Controlled  release  of  small  interfering  RNA  targeting  midkine  at-
tenuates intimal hyperplasia in vein grafts. J. Vasc. Surg. 44:633–641. 
doi:10.1016/j.jvs.2006.04.044
Berrou, E., and M. Bryckaert. 2001. Platelet-derived growth factor inhibits 
smooth muscle cell adhesion to fibronectin by ERK-dependent and ERK-
independent pathways. J. Biol. Chem. 276:39303–39309. doi:10.1074/jbc 
.M011751200
Bond, M., Y.J. Wu, G.B. Sala-Newby, and A.C. Newby. 2008. Rho GTPase, 
Rac1, regulates Skp2 levels, vascular smooth muscle cell proliferation, and 
intima formation in vitro and in vivo. Cardiovasc. Res. 80:290–298.
Cherry, S.R., D. Biniszkiewicz, L. van Parijs, D. Baltimore, and R. Jaenisch. 
2000. Retroviral expression in embryonic stem cells and hematopoietic 
stem cells. Mol. Cell. Biol. 20:7419–7426. doi:10.1128/MCB.20.20.7419- 
7426.2000
Choi, E.T., M.F. Khan, J.E. Leidenfrost, E.T. Collins, K.P. Boc, B.R. Villa, 
D.V. Novack, W.C. Parks, and D.R. Abendschein. 2004. Beta3-inte-
grin mediates smooth muscle accumulation in neointima after carotid 
ligation in mice. Circulation. 109:1564–1569.
Clowes, A.W., M.A. Reidy, and M.M. Clowes. 1983. Kinetics of cellular 
proliferation after arterial injury. I. Smooth muscle growth in the ab-
sence of endothelium. Lab. Invest. 49:327–333.
Crooke,  S.T.  2004.  Progress  in  antisense  technology.  Annu.  Rev.  Med. 
55:61–95. doi:10.1146/annurev.med.55.091902.104408
Dan, S., M. Naito, and T. Tsuruo. 1998. Selective induction of apoptosis in 
Philadelphia chromosome-positive chronic myelogenous leukemia cells 
by an inhibitor of BCR - ABL tyrosine kinase, CGP 57148. Cell Death 
Differ. 5:710–715. doi:10.1038/sj.cdd.4400400
Diaz, L.A., Jr., A.W. Friedman, X. He, R.D. Kuick, S.M. Hanash, and D.A. 
Fox. 1997. Monocyte-dependent regulation of T lymphocyte activa-
tion through CD98. Int. Immunol. 9:1221–1231. doi:10.1093/intimm/ 
9.9.1221
Fenczik, C.A., T. Sethi, J.W. Ramos, P.E. Hughes, and M.H. Ginsberg. 
1997. Complementation of dominant suppression implicates CD98 in 
integrin activation. Nature. 390:81–85. doi:10.1038/36349
Fenczik,  C.A.,  R.  Zent,  M.  Dellos,  D.A.  Calderwood,  J.  Satriano,  C. 
Kelly, and M.H. Ginsberg. 2001. Distinct domains of CD98hc regu-
late integrins and amino acid transport. J. Biol. Chem. 276:8746–8752. 
doi:10.1074/jbc.M011239200
Féral, C.C., N. Nishiya, C.A. Fenczik, H. Stuhlmann, M. Slepak, and M.H. 
Ginsberg. 2005. CD98hc (SLC3A2) mediates integrin signaling. Proc. 
Natl. Acad. Sci. USA. 102:355–360. doi:10.1073/pnas.0404852102
Féral, C.C., A. Zijlstra, E. Tkachenko, G. Prager, M.L. Gardel, M. Slepak, 
and M.H. Ginsberg. 2007. CD98hc (SLC3A2) participates in fibro-
nectin matrix assembly by mediating integrin signaling. J. Cell Biol. 
178:701–711. doi:10.1083/jcb.200705090
Fogelstrand, P., K. Osterberg, and E. Mattsson. 2005. Reduced neointima in 
vein grafts following a blockage of cell recruitment from the vein and the 
killed by drying the lumen with 2 × 20 ml of air from a syringe. To facilitate 
the removal of the adventitia, the isolated vessels were treated for 5 min with 
10 mg/ml collagenase at 37°C. The isolated media explants were cultured 
luminal side down in DMEM with 10% serum, under the weight of a culture 
plate insert. At day 4, all outgrown cells from each explant were counted 
manually under a phase contrast inverted tissue culture microscope (model 
CK2; Olympus). For flow cytometry analyses, all outgrown cells at day 4 
were collected by trypsinization, and the remaining explant tissues were di-
gested to a single-cell suspension. For proliferation analyses, BrdU was added 
to the culture media (10-µM final concentration) 2 h before harvest.
VSMC isolation and CD98hc gene deletion. VSMCs were isolated from 
the thoracic aorta from Slc3a2fl/fl mice. The cultured VSMCs were character-
ized by morphological (Fig. S4 A) and immunological criteria (flow cytometry 
quantification of smooth muscle -actin; Fig. S4 B). For all in vitro experi-
ments, VSMCs were used at passages 5–7. All culture plates were coated with 
a mix of 1 µg/ml fibronectin and 0.02% gelatin for 30 min at room tempera-
ture. The CD98hc gene was deleted using Adeno-Cre (600 particles/cell). 
Adeno-LacZ was used as control (Vector Laboratories).
Regulation of VSMC CD98 by extracellular matrix and PDGF-BB. 
700,000 Slc3a2fl/fl VSMCs were plated in a 10-cm petri dish coated with 200 µl 
Matrigel (BD) in low-glucose DMEM supplemented with 1% serum and 2% 
Matrigel. The medium was changed on day 1 to low-glucose DMEM supple-
mented with 0.2% serum and 2% Matrigel. On day 2, the cells were detached 
with dispase (BD) and replated in a 12-well plate (20,000 cells/well) coated 
with either 20 µg/ml of mouse laminin-1 (BD) or 10 µg/ml of bovine fibro-
nectin (Sigma-Aldrich). 10 µg/ml laminin-1 or 10 µg/ml fibronectin was also 
added to the media. 20 ng/ml PDGF-BB was added to half of the cells. On day 
3, the VSMC CD98 expression was analyzed using a flow cytometer.
TUNEL assay and caspase-1/3 activity on cultured VSMCs. DNA 
fragmentation on Adeno-Cre–treated VSMCs was analyzed with In Situ Cell 
Death Detection Kit, and caspase-1/3 activity was demonstrated with flow 
cytometry  using  FITC-zVAD-FMK  (CaspACE;  Promega)  according  to 
manufacturer’s instructions.
Reconstitution with human CD98hc-CD69 chimeras. Reconstituted 
cells were generated by infecting Slc3a2fl/fl VSMCs with MSCV-IRES-GFP 
retrovirus (Cherry et al., 2000) encoding human CD98hc, human CD69, or 
CD98hc-CD69 chimeras (Fig. 6 A) and GFP (Fenczik et al., 2001). Viruses 
were generated in the Phoenix EcoPack mouse ecotropic packaging cell line 
(Imgenex) by transfection (Lipofectamine Plus; Invitrogen) of the MSCV-
IRES-GFP constructs together with a pCL-Eco mouse ecotropic packaging 
plasmid (Imgenex). On days 2 and 3 after transfection, the virus-containing 
cell-culture  media  were  filtered  (0.45-µm  SFCA  filter;  Corning),  supple-
mented with 6 µg/ml polybrene (Sigma-Aldrich), and added to the VSMCs. 
2 d later, the VSMCs were replated in 12-well plates and infected with Adeno-
Cre to delete the endogenous mouse CD98hc gene. At days 3, 4, 5, and 6 after 
Adeno-Cre  treatment,  the  number  of  PI-negative/GFP-positive  cells  was 
counted using a flow cytometer.
Statistics. Data were analyzed with a two-tailed Student’s t test and a two-way 
analysis of variance with the Bonferonni posthoc test using Prism 5 software 
(GraphPad Software, Inc.).
Online supplemental material. Fig. S1 shows flow cytometry data analy-
ses on injured CAs. Fig. S2 shows the histology of different vessels and or-
gans from Slc3a2fl/flSM22-Cre and Slc3a2fl/fl mice. Fig. S3 shows CD98 
immunostaining of the dorsal aorta from Slc3a2fl/flSM22-Cre and Slc3a2fl/fl 
embryos at embryonic day 13.5. Fig. S4 shows morphological and immuno-
logical characterization of isolated VSMCs. Online supplemental material is 
available at http://www.jem.org/cgi/content/full/jem.20082845/DC1.
We gratefully acknowledge R. Weichert for assistance in genotyping the mice.2406 DEPENDENCE OF ACTIVATED VSMCS ON CD98HC | Fogelstrand et al.
surrounding  tissue.  Cardiovasc.  Res.  67:326–332.  doi:10.1016/j.cardiores 
.2005.03.027
Freyer, A.M., S.R. Johnson, and I.P. Hall. 2001. Effects of growth factors 
and extracellular matrix on survival of human airway smooth muscle 
cells. Am. J. Respir. Cell Mol. Biol. 25:569–576.
Hashimoto, Y., T. Masuko, H. Yagita, N. Endo, J. Kanazawa, and J. Tazawa. 
1983. A proliferation-associated rat cell surface antigen recognized by a 
murine monoclonal antibody. Gann. 74:819–821.
Hedin, U.L., G. Daum, and A.W. Clowes. 1997. Disruption of integrin 
alpha 5 beta 1 signaling does not impair PDGF-BB-mediated stimu-
lation of the extracellular signal-regulated kinase pathway in smooth 
muscle cells. J. Cell. Physiol. 172:109–116. doi:10.1002/(SICI)1097-
4652(199707)172:1<109::AID-JCP12>3.0.CO;2-7
Karpinski, B.A., L.H. Yang, P. Cacheris, G.D. Morle, and J.M. Leiden. 
1989. The first intron of the 4F2 heavy-chain gene contains a transcrip-
tional enhancer element that binds multiple nuclear proteins. Mol. Cell. 
Biol. 9:2588–2597.
Kokubo, T., H. Uchida, and E.T. Choi. 2007. Integrin alpha(v)beta(3) as a 
target in the prevention of neointimal hyperplasia. J. Vasc. Surg. 45(Suppl. A): 
A33–A38.
Korshunov, V.A., and B.C. Berk. 2003. Flow-induced vascular remodeling 
in the mouse: a model for carotid intima-media thickening. Arterioscler. 
Thromb. Vasc. Biol. 23:2185–2191. doi:10.1161/01.ATV.0000103120 
.06092.14
Lepore, J.J., L. Cheng, M. Min Lu, P.A. Mericko, E.E. Morrisey, and M.S. 
Parmacek. 2005. High-efficiency somatic mutagenesis in smooth muscle 
cells and cardiac myocytes in SM22alpha-Cre transgenic mice. Genesis. 
41:179–184. doi:10.1002/gene.20112
Liu, X.M., S.V. Reyna, D. Ensenat, K.J. Peyton, H. Wang, A.I. Schafer, 
and W. Durante. 2004. Platelet-derived growth factor stimulates LAT1 
gene expression in vascular smooth muscle: role in cell growth. FASEB 
J. 18:768–770. doi:10.1096/fj.03-0948com
Masuko, T., J. Abe, H. Yagita, and Y. Hashimoto. 1985. Human bladder 
cancer cell-surface antigens recognized by murine monoclonal antibodies 
raised against T24 bladder cancer cells. Jpn. J. Cancer Res. 76:386–394.
Mercurius, K.O., and A.O. Morla. 1998. Inhibition of vascular smooth muscle 
cell growth by inhibition of fibronectin matrix assembly. Circ. Res. 
82:548–556.
Mitchell, R.N., and P. Libby. 2007. Vascular remodeling in transplant vas-
culopathy. Circ. Res. 100:967–978. doi:10.1161/01.RES.0000261982 
.76892.09
Motwani, J.G., and E.J. Topol. 1998. Aortocoronary saphenous vein graft dis-
ease: pathogenesis, predisposition, and prevention. Circulation. 97:916–931.
Nakashima, Y., T.N. Wight, and K. Sueishi. 2008. Early atherosclerosis in 
humans: role of diffuse intimal thickening and extracellular matrix pro-
teoglycans. Cardiovasc. Res. 79:14–23. doi:10.1093/cvr/cvn099
Newby, A.C., and A.B. Zaltsman. 2000. Molecular mechanisms in inti-
mal  hyperplasia.  J.  Pathol.  190:300–309.  doi:10.1002/(SICI)1096-
9896(200002)190:3<300::AID-PATH596>3.0.CO;2-I
Pickering, J.G., L.H. Chow, S. Li, K.A. Rogers, E.F. Rocnik, R. Zhong, 
and B.M. Chan. 2000. alpha5beta1 integrin expression and luminal edge 
fibronectin matrix assembly by smooth muscle cells after arterial injury. 
Am. J. Pathol. 156:453–465.
Prager,  G.W.,  C.C.  Féral,  C.  Kim,  J.  Han,  and  M.H.  Ginsberg.  2007. 
CD98hc (SLC3A2) interaction with the integrin beta subunit cytoplasmic 
domain mediates adhesive signaling. J. Biol. Chem. 282:24477–24484.   
doi:10.1074/jbc.M702877200
Schwartz, R.S., and T.D. Henry. 2002. Pathophysiology of coronary artery 
restenosis. Rev. Cardiovasc. Med. 3(Suppl. 5):S4–S9.
Schwartz, S.M., D. deBlois, and E.R. O’Brien. 1995. The intima. Soil for 
atherosclerosis and restenosis. Circ. Res. 77:445–465.
Simon, D.I., Z. Dhen, P. Seifert, E.R. Edelman, C.M. Ballantyne, and C. 
Rogers. 2000. Decreased neointimal formation in Mac-1(/) mice re-
veals a role for inflammation in vascular repair after angioplasty. J. Clin. 
Invest. 105:293–300. doi:10.1172/JCI7811
Stabile, E., Y.F. Zhou, M. Saji, M. Castagna, M. Shou, T.D. Kinnaird, 
R. Baffour, M.D. Ringel, S.E. Epstein, and S. Fuchs. 2003. Akt con-
trols vascular smooth muscle cell proliferation in vitro and in vivo by 
delaying  G1/S  exit.  Circ.  Res.  93:1059–1065.  doi:10.1161/01.RES 
.0000105086.31909.1B
Su, X., J. Mi, J. Yan, P. Flevaris, Y. Lu, H. Liu, Z. Ruan, X. Wang, N. 
Kieffer, S. Chen, et al. 2008. RGT, a synthetic peptide corresponding 
to the integrin beta 3 cytoplasmic C-terminal sequence, selectively in-
hibits outside-in signaling in human platelets by disrupting the interac-
tion of integrin alpha IIb beta 3 with Src kinase. Blood. 112:592–602. 
doi:10.1182/blood-2007-09-110437
Taylor, J.M., C.P. Mack, K. Nolan, C.P. Regan, G.K. Owens, and J.T. 
Parsons. 2001. Selective expression of an endogenous inhibitor of FAK 
regulates proliferation and migration of vascular smooth muscle cells. Mol. 
Cell. Biol. 21:1565–1572. doi:10.1128/MCB.21.5.1565-1572.2001
Wagner, C.A., F. Lang, and S. Bröer. 2001. Function and structure of 
heterodimeric amino acid transporters. Am. J. Physiol. Cell Physiol. 
281:C1077–C1093.
Weinstein, I.B. 2002. Cancer. Addiction to oncogenes—the Achilles heal of 
cancer. Science. 297:63–64. doi:10.1126/science.1073096
Weinstein, I.B., and A.K. Joe. 2006. Mechanisms of disease: Oncogene 
addiction—a rationale for molecular targeting in cancer therapy. Nat. 
Clin. Pract. Oncol. 3:448–457. doi:10.1038/ncponc0558
Williams, K.J., and I. Tabas. 1995. The response-to-retention hypothesis of 
early atherogenesis. Arterioscler. Thromb. Vasc. Biol. 15:551–561.
Yagita, H., and Y. Hashimoto. 1986. Monoclonal antibodies that inhibit 
activation and proliferation of lymphocytes. II. Requisite role of the 
monoclonal antibody-defined antigen systems in activation and prolif-
eration of human and rat lymphocytes. J. Immunol. 136:2062–2068.
Zent, R., C.A. Fenczik, D.A. Calderwood, S. Liu, M. Dellos, and M.H. 
Ginsberg. 2000. Class- and splice variant-specific association of CD98 
with integrin beta cytoplasmic domains. J. Biol. Chem. 275:5059–5064. 
doi:10.1074/jbc.275.7.5059